India mulls freight reimbursement against backdrop of EU seizures
This article was originally published in Scrip
India may consider reimbursing additional freight costs borne by domestic companies that steer clear of the EU to export medicines to South America and Africa. The proposal comes against the backdrop of a spate of "illegal" seizures of transiting Indian generic drug consignments at EU ports over alleged violations of intellectual property rights.
You may also be interested in...
Gilead clarifies position on Cipla’s sub-licensing effort for remdesivir, the investigational antiviral in the global spotlight as a potential treatment for COVID-19.
Sun Pharma says that the first quarter of financial 2021 will likely be challenging across the industry with a lull in new prescriptions in India, especially in the acute and semi-chronic segments. But the firm remains upbeat about its lead psoriasis asset Ilumya, which has inched close to the $100m sales mark in its first full year of commercialization.
Physicians may have new expectations from pharma sales reps in India amid COVID-19 and teleconsulting efforts will likely see a significant uptick, at least until the pandemic plateaus, a new survey finds.